Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Celyad   /   CELYAD 2017 Nieuws

Aandeel Celyad BRU:CYAD.BL, BE0974260896

Laatste koers (eur) Verschil Volume
0,697   +0,047   (+7,23%) Dagrange 0,651 - 0,697 12.561   Gem. (3M) 70,7K

CELYAD 2017 Nieuws

Volgen
643 Posts
Pagina: «« 1 2 3 4 5 6 ... 33 »» | Laatste | Omlaag ↓
  2. lorcu 28 april 2017 09:38
    Celyad initiates second dose escalation in THINK trial in first US patient
    Initiation of the THINK trial in the US at Roswell Park Cancer Institute
    Dosing of the first patient of the second dose (1x109) in solid tumor arm
    Favorable safety profile reported on all patients treated with CAR-T NKR-2
    Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, today announced the dosing of the first patient of the second dose in the solid tumor arm of its THINK trial (THerapeutic Immunotherapy with NKR-2). This first ovarian cancer patient has been dosed at Roswell Park Cancer Institute (Buffalo, New York).
  4. lorcu 2 mei 2017 09:24

    Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents
    Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s US patents for the production of allogeneic CAR-T cells. This license agreement is related to two targets currently under development by Novartis
  14. Zo gaat dat 8 mei 2017 15:01
    Oud berichtje over de deal maar het verwoord één en ander wel duidelijk.

    GEN News Highlights More »
    May 2, 2017
    Novartis, Celyad Agree to Nonexclusive CAR T-Cell Technology Deal
    Belgium-based Celyad granted Novartis a nonexclusive license to its allogeneic chimeric antigen receptor (CAR) T-cell technology for two unspecified Novartis targets. The potentially $96 million deal includes an up-front payment and single-digit royalties on net sales of the products developed using the licensed technology. The deal gives Novartis an option to extend the license to additional targets, and/or to convert it to an exclusive license. Celyad retains the right to grant allogeneic CAR T-cell licenses to other parties.

    Christian Homsy, M.D., CEO of Celyad, commented, "This nonexclusive agreement with Novartis recognizes the importance of our IP for companies developing allogeneic CAR T-cell therapies."

    Celyad is developing its Natural Killer Receptor T-cell (NKR-T) platform for the potential treatment of a range of solid and hematologic tumors. Lead CAR T-cell candidate NKR-2 expresses the human NK receptor NKG2D, which Celyad claims binds to ligands that are expressed on 80% of cancers, giving the product potential utility against both solid and hematologic cancers. The firm is developing both allogenic and autologous NKR-2 products. The allogeneic NKR-2 CAR T-cell product has been successfully evaluated in a Phase I study in patients with acute myeloid leukemia (AML) and multiple myeloma (MM). In March, the firm received FDA clearance to start a second, U.S.- and EU-based open-label Phase Ib study, THINK, in multiple cancer indications, including five solid cancers and two hematological cancers.

    During mid-2016, Celyad and Ono Pharmaceutical inked a potentially $311.5 million deal for the allogeneic NKR-2 T-cell therapy in Japan, Korea, and Taiwan. The agreement includes an exclusive option for Ono to license the autologous KNR-2 T-cell product in the same territories.

    Celyad also has an ongoing NKR-T research collaboration with the Institut Curie in Paris, France, signed in March 2016.

    Celyad has separately been developing its C-Cure® cell therapy for heart failure, and although the European CHART-1 Phase III C-Cure study failed to meet its primary endpoint in mid-2016, the study indicated potential benefits of treatment for specific subsets of patients. Celyad is using the trial data to optimize the design of a second pivotal U.S.-based trial, CHART-2, and is looking for partners to continue C-Cure development and commercialization.

    www.genengnews.com/gen-news-highlight...
643 Posts
Pagina: «« 1 2 3 4 5 6 ... 33 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee